FairJourney Biologics establishes Supervisory Board to accelerate antibody discovery innovation
FairJourney Biologics S.A., a global leader in antibody discovery and development based in Porto, Portugal, has announced the formation of a new Supervisory Board aimed at enhancing the company’s strategic positioning and accelerating innovation in antibody research. The board, comprising distinguished industry veterans with extensive expertise in biopharmaceutical development, will focus on defining key growth avenues and optimising scientific strategies.
Strategic leadership appointments mark new chapter
Dr. Werner Lanthaler, currently CEO of investment firm Wlanholding, has been appointed Chair of the Supervisory Board. His appointment brings valuable experience from previous executive roles, including CEO of Evotec AG and CFO at Intercell AG. Dr. Lanthaler’s background includes orchestrating strategic partnerships with pharmaceutical companies, biotechnology firms, and academic institutions. His academic credentials include a Ph.D. in Economics from the University of Vienna and a master’s degree in public administration from Harvard University’s Kennedy School of Government.
The board’s composition reflects a deliberate assembly of complementary expertise in biologics research and development. Dr. Mikael Dolsten joins with over 25 years of experience, notably as Chief Scientific Officer and President of Worldwide Research, Development, and Medical at Pfizer. Dr. Tariq Ghayur brings three decades of specialised knowledge in biologics early discovery, bi- and multi-specific biologics platforms, and translational medicine, having previously held senior positions at BASF Pharma, Abbott Laboratories, and AbbVie.
Investment firms secure representation
The Supervisory Board also includes representatives from the company’s major investors. Partners Group, which acquired a majority stake in FairJourney Biologics in 2024, will be represented by Dr. Remy Hauser and Pascal Noth. GHO Capital, a European specialist investor in global healthcare holding a minority stake, will be represented by Edward de Nor.
Strategic focus on scientific advancement
The formation of this board follows Partners Group’s majority investment in 2024, signalling a phase of structured growth and strategic direction for the antibody discovery specialist. The board’s mandate appears focused on reinforcing scientific excellence while enhancing commercial partnerships.
Dr. Lanthaler highlighted his vision for the company, stating: “I am honoured to join the Supervisory Board at such a pivotal time. My goal is to foster an environment of rigorous scientific and agile decision-making that will help to further development of Fairjourney Biologics’ breakthrough antibody solutions.”
António Parada, CEO of FairJourney Biologics, emphasised the strategic importance of these appointments: “Our new board marks an exciting chapter for FairJourney Biologics. With leaders of such exceptional calibre and diverse backgrounds joining us, we are well-positioned to drive innovation and excellence in the antibody space.”
Translational focus remains central
Board member Dr. Tariq Ghayur underscored the importance of efficient development processes in biologics: “In today’s dynamic biomedical landscape, the speedy development of innovative biologics and associated technologies is key. I am eager to work with my fellow board members to ensure that our innovation not only advances scientific knowledge but also translates into tangible benefits for patients worldwide.”
Dr. Mikael Dolsten articulated the board’s collaborative ambitions: “The formation of this Board represents a unique opportunity to bridge cutting-edge research with real-world application. We’re excited to redefine the interplay between outsourcing and strategic partnering, forging stronger collaborations to drive innovation and deliver transformative solutions.”
Mikael Dolsten, Werner Lanthaler, Tariq Ghayur
